ursodeoxycholic acid concept stocks exploded across the board today. Xuantai Pharmaceutical and Gonggong Pharmaceuticals received 20CM limit up , Shuangcheng Pharmaceutical and Qianhong Pharmaceutical limit up.
news, on December 5, 2022, researchers from the University of Cambridge in the UK published a research paper titled "FXR injection may protect from SARS-CoV-2 infection by reducing ACE2" in the journal "Nature". The study shows that a drug ursodeoxycholic acid (UDCA), a drug that treats liver disease, can close the ACE2 receptor, and closes the door to the virus into cells. The drug can be used to prevent COVID-19 infection. Since the drug targets host cells rather than viruses, it may prevent future new variants of the virus, as well as other coronaviruses that may appear.
Here I would like to remind investors that the article does not mention the negative impact of closing the ACE2 receptor. In fact, the ACE2 receptor has a complex physiological effect in the human body, one of which is responsible for the regulation of blood pressure in the human body. Turning off may cause blood pressure disorders, so it is too early to be used in actual use.
And more important point is that ursodeoxycholic acid is a common liver disease drug and has passed the patent period. Therefore, ursodeoxycholic acid drug can be copied and produced in large quantities.
Ursodeoxycholic acid concept came into being today and rose sharply. Science and Technology Innovation Board Xuantai Pharmaceutical is at the right time. In its investor relations activity record released on December 1, it stated that ursodeoxycholic acid capsules were approved in July 2022, and the products will be commercially supplied in the near future. It is expected that ursodeoxycholic acid capsules and other products will bring good performance contributions. Xuantai Pharmaceutical hit the daily limit by 20% in the morning. opened in less than 1 minute, and the transaction exceeded yesterday's full-day transaction.
also stated in the convertible corporate bond prospectus released at the end of November that the fundraising product double-lowering alcohol has broad application space in the downstream markets of progesterone , ursodeoxycholic acid, plant-source cholesterol and vitamin D3. Among them, the corresponding demand for di-lower alcohol in the ursodeoxycholic acid market is about 1,700 tons/year. Overall, the downstream market demand for the company's fundraising and investment products is large and will continue to show a growth trend.
Tong Pharmaceutical also opened higher and closed higher in the early trading of , blocking the daily limit strongly, and the transaction was several times higher than yesterday. Concept stocks with related products such as Guangshengtang, Shanghai Kaibao , Fu'an Pharmaceutical , etc. all followed the sharp rise.
000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-